Contineum Therapeutics, Inc. CTNM

Annual Quarterly

FY2024 · ended Dec 31, 2024 · Revenue $0 · Filed Mar 5, 2026

Contineum Therapeutics, Inc. (CTNM) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$55.5 million. As of Sep 30, 2026 it held $244.5 million in cash and investments and $6.3 million in total debt.

Revenue
$0
Net income
$-59.98M
-41.9% vs prior year
Operating cash flow (TTM)
$-51.87M
+1.1% vs year-ago TTM
Free cash flow (TTM)
$-52.23M
+1.1% vs year-ago TTM
EPS
$-2.17
+0.5% vs prior year
Dividend per share
None
Shares outstanding
25.87M
Net cash
$238.22M
as of Sep 30, 2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CTNM (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1855175

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Revenue
—
$0
Operating income
-$68.1M
-$50.9M
Net income
-$60.0M
-$42.3M
Diluted EPS
-$2.17
-$2.18
Operating cash flow
-$55.3M
-$32.8M
Free cash flow
-$55.5M
-$33.4M
Total assets
$276.6M
$212.8M
Total liabilities
$15.7M
$14.8M
Stockholders' equity
$261.0M
$198.1M
Cash and investments
$262.9M
$204.8M
Total debt
$8.2M
$6.3M

Recent SEC filings

Form Description Filed Period
10-Q Quarterly report Nov 3, 2026 Sep 30, 2026
8-K Current report
Results of operations
 Nov 3, 2026 Nov 3, 2026
8-K Current report
Other events
 Sep 14, 2026 Sep 14, 2026
10-Q Quarterly report Jul 30, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Jul 30, 2026 Jul 30, 2026
8-K Current report
Regulation FD disclosure
 Jul 13, 2026 Jul 13, 2026

All 200 Contineum Therapeutics, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.